Pegylated interferon therapy during early pregnancy for hepatitis B infection: does it prevent vertical transmission?
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, cilt.30, sa.6, ss.745-747, 2017 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 30 Sayı: 6
- Basım Tarihi: 2017
- Doi Numarası: 10.1080/14767058.2016.1183639
- Dergi Adı: JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.745-747
- Eskişehir Osmangazi Üniversitesi Adresli: Evet
Özet
In general, interferon (IFN) is avoided during pregnancy due to the possibility of fetal side effects. We, herein, reported two child-bearing women with chronic hepatitis B (HB) infection who used pegylated interferon alfa 2b (PEG IFN alpha 2b) in first trimester unintentionally. We compared HB contracting rates of gestations in which IFN was used and not used. The cases are unique in that they could highlight the importance of IFN use in early gestation for preventing vertical transmission particularly if combined with antiviral therapy for the rest of pregnancy.